Literature DB >> 29789876

[New treatment option-apalutamide for nonmetastatic, castration-resistant prostate cancer].

B Hadaschik, A Panic1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29789876     DOI： 10.1007/s00120-018-0669-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  5 in total

Review 1.  PSMA Ligands for PET Imaging of Prostate Cancer.

Authors:  Sarah M Schwarzenboeck; Isabel Rauscher; Christina Bluemel; Wolfgang P Fendler; Steven P Rowe; Martin G Pomper; Ali Afshar-Oromieh; Ken Herrmann; Matthias Eiber
Journal:  J Nucl Med       Date:  2017-07-07       Impact factor: 10.057

2.  Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.

Authors:  Matthew R Smith; Fred Saad; Stephane Oudard; Neal Shore; Karim Fizazi; Paul Sieber; Bertrand Tombal; Ronaldo Damiao; Gavin Marx; Kurt Miller; Peter Van Veldhuizen; Juan Morote; Zhishen Ye; Roger Dansey; Carsten Goessl
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

3.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

4.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

5.  Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Authors:  Matthew R Smith; Emmanuel S Antonarakis; Charles J Ryan; William R Berry; Neal D Shore; Glenn Liu; Joshi J Alumkal; Celestia S Higano; Edna Chow Maneval; Rajesh Bandekar; Carla J de Boer; Margaret K Yu; Dana E Rathkopf
Journal:  Eur Urol       Date:  2016-05-06       Impact factor: 20.096
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.